AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17096718
Drug: HL-350 (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HL-350 (0.35 g/100 mL)
Trial: 15543442
Drug: Standard Constraint‐Induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Constraint‐Induced Movement therapy (matched group of 12 subjects)
Trial: 27859251
Drug: Paediatric fixed-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paediatric fixed-dose combination (FDC) zidovudine/lamivudine/nevirapine (60/30/50 mg) tablet
Trial: 26075487
Drug: Cariprazine 6-9
RxNorm normalized name: cariprazine 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cariprazine 6-9 mg/d
Trial: 11036827
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil derived (n‐3) fatty acid supplementation (3‐6 capsules/day, 40 mg/kg body weight)
Trial: 11036827
Drug: Olive/corn oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive/corn oil capsule supplement (control)
Trial: 8847860
Drug: Spironolactone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (100 mg once daily for 1 week)
Trial: 8847860
Drug: Placebo (once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (once daily for 1 week)
Trial: 3519142
Drug: Porcine intestinal
RxNorm normalized name: porcine intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine intestinal mucosa heparin
Trial: 27466718
Drug: Isunakinra (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isunakinra (5 mg/mL)
Trial: 27466718
Drug: Isunakinra (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isunakinra (20 mg/mL)
Trial: 27466718
Drug: Isunakinra (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isunakinra (5 mg/mL) and (20 mg/mL)
Trial: 26343102
Drug: Self-administered exercises
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered exercises based on Tuina techniques
Trial: 23833362
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin alone (Group-1): One drop 6 times/day for 3 days before surgery and one drop 4 times on the day of surgery
Trial: 23833362
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin with flurbiprofen (Group-2): One drop 6 times/day for 3 days before surgery and one drop 4 times on the day of surgery, plus flurbiprofen one drop 4 times/day for 3 days before and on the day of surgery
Trial: 21912022
Drug: Cyclo 10
RxNorm normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclo 10 mg/kg monthly for six months then every two months for 12 months (Group I)
Trial: 21912022
Drug: Cyclo 5
RxNorm normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclo 5 mg/kg monthly for six months then every two months for 36 months (Group II)
Trial: 21912022
Drug: Cyclo 10
RxNorm normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclo 10 mg/kg (Group I)
Trial: 21912022
Drug: Cyclo 5
RxNorm normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cyclo 5 mg/kg (Group II)
Trial: 19167276
Drug: 200mg (E)-entacapone
RxNorm normalized name: entacapone 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg (E)-entacapone tablet formulation
Trial: 16095445
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with remifentanil (1 microg kg‐1 remifentanil + 0.5 mg kg‐1 propofol)
Trial: 16095445
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with alfentanil (10 microg kg‐1 alfentanil + 0.5 mg kg‐1 propofol)
Trial: 16095445
Drug: Propofol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.75 mg kg‐1)
Trial: 7810806
Drug: Total IgG
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total IgG antibodies
Trial: 7810806
Drug: IgG4 antibodies
RxNorm normalized name: recombinant human IgG4 monoclonal antibody against FGF19
DrugBank: HH-009 (DB18727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG4 antibodies
Trial: 7810806
Drug: IgG1 antibodies
RxNorm normalized name: Humanized monoclonal antibody HU3F8-IGG1
DrugBank: Naxitamab (DB15965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IgG1 antibodies
Trial: 7810806
Drug: IgG2 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG2 and IgG3 antibodies
Trial: 3387717
Drug: Random walk
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Random walk model applied to treatment groups
Trial: 22101745
Drug: Pramipexole (PPX)
DrugBank: Pramipexole (DB00413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pramipexole (PPX) 0.25-0.75 mg
Trial: 22101745
Drug: Dual-release levodopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-release levodopa/benserazide (L/B) 125-375 mg
Trial: 22101745
Drug: Dual-release levodopa/benserazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-release levodopa/benserazide (L/B)
Trial: 3651281
Drug: atracurium 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.4 mg kg‐1
Trial: 19196814
Drug: Inhaled beclometasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclometasone (200 microg day(‐1)) + Theophylline (400 mg day(‐1))
Trial: 19196814
Drug: Theophylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (400 mg day(‐1))
Trial: 19196814
Drug: Inhaled beclometasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclometasone (200 microg day(‐1))
Trial: 15103566
Drug: Immunonutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunonutrition solution containing arginine, nucleotides, and polyunsaturated fatty acids
Trial: 15103566
Drug: Isocaloric solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric solution
Trial: 11339730
Drug: Intraosseous infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraosseous infusion using the bone injection gun (BIG)
Trial: 9072603
Drug: Daily prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily prophylaxis (group 2, 65 patients)
Trial: 9072603
Drug: Daily prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily prophylaxis (group 2)
Trial: 7701881
Drug: Hydrogen peroxide
RxNorm normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrogen peroxide cream (Microcid)
Trial: 7701881
Drug: Fusidic acid
RxNorm normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fusidic acid cream/gel (Fucidin)
Trial: 3427696
Drug: Cefoxitin 2
RxNorm normalized name: cefoxitin 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoxitin 2 g IV every 8 hours
Trial: 3427696
Drug: Cefotaxime 2
RxNorm normalized name: cefotaxime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 2 g IV every 8 hours
Trial: 3427696
Drug: Moxalactam 2
RxNorm normalized name: Moxalactam
DrugBank: Moxalactam (hydrolyzed) (DB04740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxalactam 2 g IV every 8 hours
Trial: 3427696
Drug: Aztreonam 2
RxNorm normalized name: aztreonam 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam 2 g IV every 8 hours
Trial: 31398135
Drug: Two-stage deployment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-stage deployment solution for PHEV power management applications
Trial: 29540445
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-Acetylcysteine (NAC) 2.4 g per day
Trial: 26883688
Drug: fesoterodine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fesoterodine with topical vaginal estrogen
Trial: 19358990
Drug: Propofol 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.25 mg/kg
Trial: 10328274
Drug: Rectal-scalp temperature
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal-scalp temperature difference greater than 4 degrees C; Mean = 6.7, Range = 6.0-7.4; At the time of clinical brain death
Trial: 10328274
Drug: Rectal-abdomen and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal-abdomen and rectal-mastoid temperature differences; No specific values reported
Trial: 1566985
Drug: Sequential siting
RxNorm normalized name: SOLO SITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential siting in separate spaces
Trial: 4051157
Drug: Oral dantrolene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dantrolene 1.5 mg/kg administered orally 4 hours pre-operatively
Trial: 22776567
Drug: Optimized acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized acupuncture therapy
Trial: 7986667
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg amlodipine racemate
Trial: 2663318
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg ibuprofen
Trial: 26414724
Drug: Placental matrix‐derived
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placental matrix‐derived mesenchymal stem cells (PM‐MSCs) injection
Trial: 18510173
Drug: Oral Genetaxyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Genetaxyl at doses of 60 mg/m2, 120 mg/m2, and 180 mg/m2 with 10 mg/kg of oral cyclosporin A
Trial: 18510173
Drug: Intravenous Genetaxyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Genetaxyl (175 mg/m2, 3-h infusion)
Trial: 18510173
Drug: Intravenous Genaxyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Genaxyl (175 mg/m2, 3-h infusion)
Trial: 18510173
Drug: Generic i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic i.v. paclitaxel (Genaxol, containing 50% CrEL; 175 mg/m2, 3-h infusion)
Trial: 16585987
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily topical 1% pimecrolimus cream
Trial: 16585987
Drug: Twice weekly
RxNorm normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice weekly narrowband UVB
Trial: 16585987
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (pimecrolimus + narrowband UVB)
Trial: 26037006
Drug: Tablet-based application
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based application and brochure (N=22)
Trial: 16025784
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (sleep hygiene)
Trial: 7734256
Drug: Continuous systemic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous systemic i.v. butorphanol infusion (83.3 micrograms h‐1)
Trial: 7734256
Drug: Continuous brachial
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous brachial plexus infusion of butorphanol (83.3 micrograms h‐1)
Trial: 6106785
Drug: Oestrogen supplements
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen supplements
Trial: 6106785
Drug: Defaulted from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defaulted from oestrogen therapy
Trial: 6106785
Drug: Oestrogen dosage
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogen dosage
Trial: 28114795
Drug: Lactase dietary
RxNorm normalized name: Lactase
DrugBank: Tilactase (DB13761)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactase dietary supplement
Trial: 25733467
Drug: Biofortified maize
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofortified maize (34 μg zinc/g grain)
Trial: 25733467
Drug: Fortified maize
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified maize (60 μg zinc/g)
Trial: 25733467
Drug: Control maize
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control maize (21 μg zinc/g)
Trial: 17277392
Drug: Protein kinase
RxNorm normalized name: Protein kinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein kinase C inhibitors
Trial: 17277392
Drug: Intravitreal steroid
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal steroid injections
Trial: 17277392
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone inhibitors
Trial: 1562756
Drug: Aldose reductase
RxNorm normalized name: Aldose reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldose reductase inhibitors
Trial: 17277392
Drug: Advanced glycation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced glycation end-products inhibitors
Trial: 8239106
Drug: Continuous nebulization
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous nebulization of 30 mg albuterol over 110 minutes
Trial: 8239106
Drug: Intermittent nebulization
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent nebulization of 30 mg albuterol over 110 minutes
Trial: 8239106
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Continuous and Intermittent nebulization)
Trial: 3116985
Drug: Nicardipine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 50 mg b.i.d. for 3 weeks
Trial: 12614743
Drug: High‐dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose intravenous methylprednisolone pulse therapy (1 g per day for 3 successive days, repeated 3 times within 3 weeks) followed by 24‐Gy orbital radiotherapy
Trial: 12614743
Drug: High‐dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose intravenous methylprednisolone pulse therapy without orbital radiotherapy
Trial: 1663163
Drug: lisinopril (10‐40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lisinopril (10‐40 mg)
Trial: 1663163
Drug: enalapril (5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enalapril (5‐20 mg)
Trial: 7160424
Drug: Effervescent tablets
RxNorm normalized name: Hydralyte Effervescent Tablets Berry
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent tablets (1200 mg)
Trial: 7160424
Drug: Enteric coated
RxNorm normalized name: Mesasal Enteric Coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric coated tablets (650 mg)
Trial: 7160424
Drug: Sodium salicylate
RxNorm normalized name: Sodium Salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium salicylate (1.0 g)
Trial: 31399147
Drug: FIT039-releasing transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIT039-releasing transdermal patch
Trial: 28130749
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin (IA) + methylprednisolone
Trial: 28130749
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin (IA) + IVIG
Trial: 28130749
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin (IA) + methylprednisolone (group C1)
Trial: 28130749
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin (IA) + IVIG (group C2)
Trial: 28130749
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin (IA) alone (group C)
Trial: 24822268
Drug: Levamisole (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (50 mg) and low-dose prednisolone (5 mg)
Trial: 21728748
Drug: Occlusal splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal splint therapy for 6 months
Trial: 11439206
Drug: Accelerated radiotherapy
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated radiotherapy (ART) - 1.8 Gy twice a day to a dose of 59.4 Gy in 33 fractions over 24 days
Trial: 11439206
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (CRT) - 2 Gy/day to a dose of 70 Gy in 35 fractions over 49 days
Trial: 773801
Drug: Sulpiride (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulpiride (100 mg i.m. twice daily for 12 days, then 50 mg orally three times daily for 48 days)
Trial: 28606000
Drug: Trauma-focused cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-focused cognitive behavior therapy
Trial: 27558585
Drug: Meratrim (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meratrim (400 mg twice daily)
Trial: 22631032
Drug: ASA 81
RxNorm normalized name: ASA 81 MG Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 81 mg
Trial: 22631032
Drug: ASA 81
RxNorm normalized name: ASA 81 MG Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASA 81 mg + esomeprazole 20 mg
Trial: 19553142
Drug: Atorvastatin (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10-20 mg once per day for 12 weeks)
Trial: 16619571
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral pilocarpine 3 times a day during radiotherapy for 12 weeks
Trial: 10781275
Drug: Propofol plus
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol plus alfentanil 100 ng/ml
Trial: 6355247
Drug: IPG (immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPG (immunotherapy with polymerized whole grass)
Trial: 27075909
Drug: LD +
RxNorm normalized name: Children's Tylenol Cold + Flu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD + MCT (l‐leucine 1.2 g, cholecalciferol 20 μg, 6 g medium‐chain triglycerides)
Trial: 27075909
Drug: LD +
RxNorm normalized name: Children's Tylenol Cold + Flu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD + LCT (l‐leucine 1.2 g, cholecalciferol 20 μg, 6 g long‐chain triglycerides)
Trial: 22080632
Drug: C1‐esterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1‐esterase inhibitor infusion (12,000 U) in addition to conventional treatment
Trial: 22080632
Drug: C1‐esterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C1‐esterase inhibitor infusion
Trial: 19535971
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg/amlodipine 2.5 mg
Trial: 19535971
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg/amlodipine 5 mg
Trial: 19535971
Drug: Atenolol 25
RxNorm normalized name: atenolol 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 25 mg alone
Trial: 19535971
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg alone
Trial: 19535971
Drug: Atenolol/amlodipine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol/amlodipine combination
Trial: 15872126
Drug: Ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 4 mg iv given at the end of surgery
Trial: 12566894
Drug: 1-hour paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1-hour paclitaxel infusion
Trial: 10550134
Drug: 3-hour paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3-hour paclitaxel infusion
Trial: 8664454
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg BN52021 (paf-receptor antagonist) injected twice just before vascular cannulation and before cross-clamp release
Trial: 2363546
Drug: 3 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg.kg‐1 propofol
Trial: 2363546
Drug: 3 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg.kg‐1 propofol + 1.5 mg.kg‐1 suxamethonium
Trial: 369925
Drug: oxaprozin 600
RxNorm normalized name: oxaprozin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaprozin 600 mg/day
Trial: 369925
Drug: oxaprozin 1200
RxNorm normalized name: Oxaprozin
DrugBank: Oxaprozin (DB00991)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oxaprozin 1200 mg/day
Trial: 369925
Drug: aspirin 3900
RxNorm normalized name: aspirin 3900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: aspirin 3900 mg/day
Trial: 25963394
Drug: Expressive writing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expressive writing treatments focusing on trauma, sexuality, or daily life (control condition)
Trial: 15041597
Drug: Lidocaine 2%
RxNorm normalized name: LIDOCAINE 2% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 2% (bolus injection of 1.5 mg/kg in 10 min followed by an IV infusion of 1.5 mg/kg/h)
Trial: 11765119
Drug: Empiric use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric use of GP IIb/IIIa inhibitors